1. Kostelny SA, Link BK, Tso JY, Vasquez M, Jorgensen BH, Wang H et al. Humanization and characterization of the anti-HLA-DR antibody 1D10. Int J Cancer 2001; 93: 556–565.
2. Shi JD, Bullock C, Hall WC, Wescott V, Wang H, Levitt DJ et al. In vivo pharmacodynamic effects of Hu1D10 (Remitogen), a humanized antibody reactive against a polymorphic determinant of HLA-DR expressed on B cells. Leukemia Lymphoma 2002; 43: 1303–1312.
3. Link BK, Wang H, Byrd JC, Leonard JP, Davis TA, Flinn I et al. Phase I study of Hu1D10 monoclonal antibody in patients with B-cell lymphoma. ASCO 2001; 1135.
4. Link BK, Wang H, Byrd JC, Leonard JP, Flinn I, Davis TA et al. Humanized anti-HLA-DR monoclonal antibody Hu1D10 for the treatment of relapsed non-Hodgkin's lymphoma: a phase I trial. ASH 2001; 4703.
5. Abhyankar VV, Lucas MS, Lin TS, Mone A, Stock W, Aron JL et al. Phase I study of thrice weekly dosing of Hu1D10 in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): preliminary observations in toxicity and biologic data. ASCO 2002; 1069